Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti 1,2,3, Gunar Günther 4,5, Claude Leu 4, Daniela Cirillo 6, Raquel Duarte 7,8,9,10, Alberto L. García-Basteiro 11,12, Delia Goletti 13, Mateja Jankovic 14, Liga Kuksa 15,16, Florian P. Maurer 17,18,19, Frédéric Méchaï 20, Simon Tiberi 21,22, Frank van Leth 23,24, Nicolas Veziris 2,25,26 and Christoph Lange 19,27,28,29 on behalf of the Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet)

1Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France. 2APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France. 3APHP, Infectious Disease Unit, Avicenne Hospital, Bobigny, France. 4Department of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 5Department of Internal Medicine, School of Medicine, University of Namibia, Windhoek, Namibia. 6WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milano, Italy. 7Epidemiology Research Unit (EpiUnit), Institute of Public Health, University of Porto, Porto, Portugal. 8Servicio de Pneumología, Centro Hospitalar de Vila Nova de Gaia/Esposito, Vila Nova de Gaia, Portugal. 9National Tuberculosis Program, Directorate-General of Health, Lisbon, Portugal. 10Centro de Investigación en Salud Pública, Ciencias Forenses y Educación Médica, Faculty of Medicine, University of Porto, Porto, Portugal. 11National and Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany. 12Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 13German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany. 14APHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France. 15Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK. 16Royal London Hospital, Barts Health National Health Service Trust, London, UK. 17VU University, Department of Health Sciences, Amsterdam, The Netherlands. 18Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. 19APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine, Département de bactériologie, Paris, France. 20Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France. 21Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. 22Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany. 23Baylor College of Medicine and Texas Children’s Hospital, Global TB Program, Houston, TX, USA.

Corresponding author: Lorenzo Guglielmetti (lorenzo.guglielmetti@aphp.fr)

Shareable abstract (@ERSPublications)

Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh


This single-page version can be shared freely online.

To the Editor:

Rifapentine, a synthetic derivate of rifampicin which was developed in 1965, has interesting pharmacological properties, including a long terminal half-life (13 h, compared to 2–3 h for rifampicin) and promising bactericidal activity against Mycobacterium tuberculosis. Despite being approved in 1998 by the US Food and Drug Administration (FDA) for the treatment of pulmonary tuberculosis, its global use has been limited by unavailability. In the past decade, new evidence has emerged to define rifapentine as a key component for treatment of active disease and latent infection with M. tuberculosis (LTBI).